Published in Protein Sci on March 01, 2011
Expressing the human proteome for affinity proteomics: optimising expression of soluble protein domains and in vivo biotinylation. N Biotechnol (2011) 0.85
Accurate de novo design of hyperstable constrained peptides. Nature (2016) 0.78
Modified recombinant proteins can be exported via the Sec pathway in Escherichia coli. PLoS One (2012) 0.77
Functional production of a soluble and secreted single-chain antibody by a bacterial secretion system. PLoS One (2014) 0.76
Novel signal peptides improve the secretion of recombinant Staphylococcus aureus Alpha toxinH35L in Escherichia coli. AMB Express (2017) 0.75
Folding Optimization In Vivo Uncovers New Chaperones. J Mol Biol (2015) 0.75
A combination of HPLC and automated data analysis for monitoring the efficiency of high-pressure homogenization. Microb Cell Fact (2017) 0.75
Crystal structures explain functional properties of two E. coli porins. Nature (1992) 10.38
Type V protein secretion pathway: the autotransporter story. Microbiol Mol Biol Rev (2004) 5.80
A method for efficient isotopic labeling of recombinant proteins. J Biomol NMR (2001) 4.96
Recombinant protein folding and misfolding in Escherichia coli. Nat Biotechnol (2004) 4.47
The N-end rule in bacteria. Science (1991) 4.21
Structure of the outer membrane protein A transmembrane domain. Nat Struct Biol (1998) 4.06
Human Mig chemokine: biochemical and functional characterization. J Exp Med (1995) 2.67
Secretory and extracellular production of recombinant proteins using Escherichia coli. Appl Microbiol Biotechnol (2004) 2.41
Improved solubility of TEV protease by directed evolution. J Biotechnol (2005) 2.35
Protein folding in the bacterial periplasm. J Bacteriol (1997) 2.11
The use of systematic N- and C-terminal deletions to promote production and structural studies of recombinant proteins. Protein Expr Purif (2007) 2.10
An outer membrane protein (OmpA) of Escherichia coli K-12 undergoes a conformational change during export. J Biol Chem (1986) 1.92
A periplasmic protein (Skp) of Escherichia coli selectively binds a class of outer membrane proteins. Mol Microbiol (1996) 1.86
Thioredoxins and glutaredoxins as facilitators of protein folding. Biochim Biophys Acta (2008) 1.85
Incorporation of heterologous outer membrane and periplasmic proteins into Escherichia coli outer membrane vesicles. J Biol Chem (2003) 1.76
Lipopolysaccharide structure required for in vitro trimerization of Escherichia coli OmpF porin. J Bacteriol (1991) 1.62
Secretion of virulence determinants by the general secretory pathway in gram-negative pathogens: an evolving story. Microbes Infect (2000) 1.53
The cryptic general secretory pathway (gsp) operon of Escherichia coli K-12 encodes functional proteins. J Bacteriol (1996) 1.35
The disulphide isomerase DsbC cooperates with the oxidase DsbA in a DsbD-independent manner. Mol Microbiol (2007) 1.21
Trimerization of an in vitro synthesized OmpF porin of Escherichia coli outer membrane. J Biol Chem (1991) 1.19
Proteome-based identification of fusion partner for high-level extracellular production of recombinant proteins in Escherichia coli. Biotechnol Bioeng (2008) 1.16
Cell and process design for targeting of recombinant protein into the culture medium of Escherichia coli. Appl Microbiol Biotechnol (2002) 1.16
The BON domain: a putative membrane-binding domain. Trends Biochem Sci (2003) 1.10
Membrane protein folding on the example of outer membrane protein A of Escherichia coli. Cell Mol Life Sci (2003) 1.09
Soluble CPG15 expressed during early development rescues cortical progenitors from apoptosis. Nat Neurosci (2005) 1.09
Type I receptor binding of bone morphogenetic protein 6 is dependent on N-glycosylation of the ligand. FEBS J (2007) 1.09
The CXC chemokine MIG/CXCL9 is important in innate immunity against Streptococcus pyogenes. J Infect Dis (2007) 1.08
High throughput production of recombinant human proteins for crystallography. Methods Mol Biol (2008) 1.08
Cationic peptide antimicrobials induce selective transcription of micF and osmY in Escherichia coli. Biochim Biophys Acta (2000) 1.05
Scalable high-throughput micro-expression device for recombinant proteins. Biotechniques (2004) 1.05
Specific secretion of active single-chain Fv antibodies into the supernatants of Escherichia coli cultures by use of the hemolysin system. Appl Environ Microbiol (2000) 1.03
Comparison of the extracellular proteomes of Escherichia coli B and K-12 strains during high cell density cultivation. Proteomics (2008) 1.02
Extracellular accumulation of recombinant proteins fused to the carrier protein YebF in Escherichia coli. Nat Biotechnol (2005) 1.00
SRP and Sec pathway leader peptides for antibody phage display and antibody fragment production in E. coli. N Biotechnol (2008) 0.98
Excretion of human beta-endorphin into culture medium by using outer membrane protein F as a fusion partner in recombinant Escherichia coli. Appl Environ Microbiol (2002) 0.97
One hundred seventy-fold increase in excretion of an FV fragment-tumor necrosis factor alpha fusion protein (sFV/TNF-alpha) from Escherichia coli caused by the synergistic effects of glycine and triton X-100. Appl Environ Microbiol (1998) 0.96
pSKAP/S: An expression vector for the production of single-chain Fv alkaline phosphatase fusion proteins. Protein Expr Purif (1999) 0.95
Formation of disulphide bonds during secretion of proteins through the periplasmic-independent type I pathway. Mol Microbiol (2001) 0.93
ProteinCCD: enabling the design of protein truncation constructs for expression and crystallization experiments. Nucleic Acids Res (2009) 0.92
Mycobacterium tuberculosis Rv0899 adopts a mixed alpha/beta-structure and does not form a transmembrane beta-barrel. Biochemistry (2010) 0.91
E. coli hemolysin interactions with prokaryotic and eukaryotic cell membranes. Bioessays (1992) 0.90
Proteomic analysis of extracellular proteins from Escherichia coli W3110. J Proteome Res (2006) 0.89
A protein with sequence identity to Skp (FirA) supports protein translocation into plasma membrane vesicles of Escherichia coli. FEBS Lett (1990) 0.88
Construction of an excretion vector and extracellular production of human growth hormone from Escherichia coli. Gene (1987) 0.86
X-ray structure and site-directed mutagenesis analysis of the Escherichia coli colicin M immunity protein. J Bacteriol (2010) 0.85
Cloning and hemolysin-mediated secretory expression of a codon-optimized synthetic human interleukin-6 gene in Escherichia coli. Protein Expr Purif (2002) 0.84
Efficient production of extracellular proteins with Escherichia coli by means of optimized coexpression of bacteriocin release proteins. J Biotechnol (2009) 0.84
Identification of osteopontin phosphorylation sites involved in bone remodeling and inhibition of pathological calcification. J Cell Biochem (2008) 0.83
Expression, purification and characterization of B72.3 Fv fragments. Biochem J (1993) 0.83
Pore-forming colicins: synthesis, extracellular release, mode of action, immunity. Biochimie (1988) 0.81
An E. coli over-expression system for multiply-phosphorylated proteins and its use in a study of calcium phosphate sequestration by novel recombinant phosphopeptides. Protein Expr Purif (2009) 0.80
A software tool to accelerate design of protein constructs for recombinant expression. Protein Expr Purif (2010) 0.80
Expression of the human activin type I and II receptor extracellular domains in Pichia pastoris. Protein Expr Purif (2005) 0.78
Generation and use of recombinant human bone sialoprotein and osteopontin for hydroxyapatite studies. Connect Tissue Res (1996) 0.78
Expression and purification of bioactive high-purity mouse monokine induced by IFN-gamma in Escherichia coli. Protein Expr Purif (2007) 0.76
Use of colicin-based genetic tools for studying bacterial protein transport. Biochimie (2002) 0.76
Factors that influence the extracellular expression of streptavidin in Escherichia coli using a bacteriocin release protein. Appl Microbiol Biotechnol (2008) 0.76
Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc Natl Acad Sci U S A (2006) 4.45
Protein production and purification. Nat Methods (2008) 3.97
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A (2007) 3.21
In situ proteolysis for protein crystallization and structure determination. Nat Methods (2007) 3.05
Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol (2012) 2.58
A roadmap to generate renewable protein binders to the human proteome. Nat Methods (2011) 2.38
The use of systematic N- and C-terminal deletions to promote production and structural studies of recombinant proteins. Protein Expr Purif (2007) 2.10
Structural basis for protein-protein interactions in the 14-3-3 protein family. Proc Natl Acad Sci U S A (2006) 1.95
The crystal structure of the human toll-like receptor 10 cytoplasmic domain reveals a putative signaling dimer. J Biol Chem (2008) 1.89
Structural diversity in the RGS domain and its interaction with heterotrimeric G protein alpha-subunits. Proc Natl Acad Sci U S A (2008) 1.72
Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase. Proc Natl Acad Sci U S A (2006) 1.57
The DEXD/H-box RNA helicase DDX19 is regulated by an {alpha}-helical switch. J Biol Chem (2009) 1.39
Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor. J Med Chem (2010) 1.33
Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J Med Chem (2009) 1.31
His tag effect on solubility of human proteins produced in Escherichia coli: a comparison between four expression vectors. J Struct Funct Genomics (2004) 1.31
Comparative structural analysis of human DEAD-box RNA helicases. PLoS One (2010) 1.21
Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888. Biochemistry (2010) 1.17
A pilot project to generate affinity reagents to human proteins. Nat Methods (2008) 1.16
Towards proteome scale antibody selections using phage display. N Biotechnol (2009) 1.15
Inhibition of protein-protein interactions: the discovery of druglike beta-catenin inhibitors by combining virtual and biophysical screening. Proteins (2006) 1.15
Zinc binding catalytic domain of human tankyrase 1. J Mol Biol (2008) 1.09
The scientific impact of the Structural Genomics Consortium: a protein family and ligand-centered approach to medically-relevant human proteins. J Struct Funct Genomics (2007) 1.07
Crystal structure of human cytosolic 5'-nucleotidase II: insights into allosteric regulation and substrate recognition. J Biol Chem (2007) 1.02
Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships. J Med Chem (2008) 1.01
Structural proteomics: developments in structure-to-function predictions. Trends Biotechnol (2002) 1.01
Functional proteomics defines the molecular switch underlying FGF receptor trafficking and cellular outputs. Mol Cell (2013) 1.00
Insights for the development of specific kinase inhibitors by targeted structural genomics. Drug Discov Today (2007) 0.96
Structure of the synthetase domain of human CTP synthetase, a target for anticancer therapy. Acta Crystallogr Sect F Struct Biol Cryst Commun (2006) 0.91
Mechanism of action of pyridazine analogues on protein tyrosine phosphatase 1B (PTP1B). Bioorg Med Chem Lett (2004) 0.91
The crystal structure of a human PP2A phosphatase activator reveals a novel fold and highly conserved cleft implicated in protein-protein interactions. J Biol Chem (2006) 0.90
ADAM12 is expressed in the tumour vasculature and mediates ectodomain shedding of several membrane-anchored endothelial proteins. Biochem J (2013) 0.90
Biochemical discrimination between selenium and sulfur 1: a single residue provides selenium specificity to human selenocysteine lyase. PLoS One (2012) 0.89
First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem (2009) 0.88
Structural and biophysical characterization of human myo-inositol oxygenase. J Biol Chem (2008) 0.88
Crystal structure of human RNA helicase A (DHX9): structural basis for unselective nucleotide base binding in a DEAD-box variant protein. J Mol Biol (2010) 0.88
The crystal structure of human cleavage and polyadenylation specific factor-5 reveals a dimeric Nudix protein with a conserved catalytic site. Proteins (2008) 0.87
Crystal structure of human inosine triphosphatase. Substrate binding and implication of the inosine triphosphatase deficiency mutation P32T. J Biol Chem (2006) 0.87
Identification of structure-activity relationships from screening a structurally compact DNA-encoded chemical library. Angew Chem Int Ed Engl (2015) 0.87
Selection of affibody molecules to the ligand-binding site of the insulin-like growth factor-1 receptor. Biotechnol Appl Biochem (2010) 0.86
Screening methods to determine biophysical properties of proteins in structural genomics. Anal Biochem (2003) 0.86
First structure of a eukaryotic phosphohistidine phosphatase. J Biol Chem (2006) 0.86
The structure of the PP2A regulatory subunit B56 gamma: the remaining piece of the PP2A jigsaw puzzle. Proteins (2009) 0.86
Structure-based screening and design in drug discovery. Drug Discov Today (2002) 0.86
Expressing the human proteome for affinity proteomics: optimising expression of soluble protein domains and in vivo biotinylation. N Biotechnol (2011) 0.85
Open-access public-private partnerships to enable drug discovery--new approaches. IDrugs (2010) 0.83
Recombinant renewable polyclonal antibodies. MAbs (2015) 0.83
PARP inhibitor with selectivity toward ADP-ribosyltransferase ARTD3/PARP3. ACS Chem Biol (2013) 0.83
Recombinant protein quality evaluation: proposal for a minimal information standard. Stand Genomic Sci (2011) 0.82
Crystal structure of the ATPase domain of the human AAA+ protein paraplegin/SPG7. PLoS One (2009) 0.82
Structure of human argininosuccinate synthetase. Acta Crystallogr D Biol Crystallogr (2008) 0.81
Discovery of ligands for ADP-ribosyltransferases via docking-based virtual screening. J Med Chem (2012) 0.81
Structural basis of tumor suppressor in lung cancer 1 (TSLC1) binding to differentially expressed in adenocarcinoma of the lung (DAL-1/4.1B). J Biol Chem (2010) 0.80
The crystal structure of the Dachshund domain of human SnoN reveals flexibility in the putative protein interaction surface. PLoS One (2010) 0.80
A software tool to accelerate design of protein constructs for recombinant expression. Protein Expr Purif (2010) 0.80
Corrigendum: The promise and peril of chemical probes. Nat Chem Biol (2015) 0.79
Substrate specificity and oligomerization of human GMP synthetase. J Mol Biol (2013) 0.79
Screening of genetic parameters for soluble protein expression in Escherichia coli. Protein Expr Purif (2010) 0.78
Crystal structure of human diphosphoinositol phosphatase 1. Proteins (2009) 0.78
Identification and characterization of a small-molecule inhibitor of death-associated protein kinase 1. Chembiochem (2014) 0.77
Selection and characterisation of affibody molecules inhibiting the interaction between Ras and Raf in vitro. N Biotechnol (2010) 0.77
Heterologous expression and purification of an active human TRPV3 ion channel. FEBS J (2013) 0.77
Chemical probes to study ADP-ribosylation: synthesis and biochemical evaluation of inhibitors of the human ADP-ribosyltransferase ARTD3/PARP3. J Med Chem (2013) 0.76
Pan-pathway based interaction profiling of FDA-approved nucleoside and nucleobase analogs with enzymes of the human nucleotide metabolism. PLoS One (2012) 0.76
Backbone 1H, 13C and 15N resonance assignment of the N-terminal 24 kDa fragment of the gyrase B subunit from E. coli. J Biomol NMR (2002) 0.75
Medium-throughput production of recombinant human proteins: protein production in E. coli. Methods Mol Biol (2014) 0.75
Structural proteomics: lessons learnt from the early case studies. Farmaco (2002) 0.75